Analysts Offer Insights on Healthcare Companies: Astrana Health (ASTH), Becton Dickinson (BDX) and United Therapeutics (UTHR)
Analysts fell to the sidelines weighing in on Astrana Health (ASTH – Research Report), Becton Dickinson (BDX – Research Report) and United Therapeutics (UTHR – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Astrana Health (ASTH)
In a report released today, Matthew Gillmor CFA from KeyBanc maintained a Hold rating on Astrana Health. The company’s shares closed last Monday at $26.32, close to its 52-week low of $23.12.
According to TipRanks.com, CFA is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Astrana Health with a $35.00 average price target, which is a 45.6% upside from current levels. In a report released today, TipRanks – OpenAI also reiterated a Hold rating on the stock with a $28.00 price target.
See the top stocks recommended by analysts >>
Becton Dickinson (BDX)
In a report released yesterday, Travis Steed from Bank of America Securities maintained a Hold rating on Becton Dickinson, with a price target of $221.00. The company’s shares closed last Monday at $176.54.
According to TipRanks.com, Steed is a 4-star analyst with an average return of
Becton Dickinson has an analyst consensus of Moderate Buy, with a price target consensus of $191.20, which is a 9.8% upside from current levels. In a report issued on February 24, RBC Capital also maintained a Hold rating on the stock with a $195.00 price target.
United Therapeutics (UTHR)
In a report released yesterday, Jason Gerberry from Bank of America Securities reiterated a Hold rating on United Therapeutics, with a price target of $569.00. The company’s shares closed last Monday at $513.82.
According to TipRanks.com, Gerberry is a 5-star analyst with an average return of
Currently, the analyst consensus on United Therapeutics is a Moderate Buy with an average price target of $528.70, representing a 3.8% upside. In a report issued on February 25, BTIG also maintained a Hold rating on the stock.
